$SGMO For the Hemophilia A gene therapy program, an additional four months of expression data were presented for giroctocogene fitelparvovec showing sustained FVIII activity levels reflecting a mean of approximately 71% between weeks 9 and 52 in patients treated with a dose of 3E13 vg/kg of the viral vector. Patients with data beyond 52 weeks show consistent FVIII levels. Importantly, there have been no bleeds with this treated cohort. Patients are currently being enrolled in a Phase 3 lead-in study with plans to dose the first patient later this year.
  • 5
5 Likes